FDA Approvals in Oncology: July-September 2024
This quarter’s 16 approvals include a first-in-class cell therapeutic, a flurry of new options for EGFR-mutated lung cancer, and...
Tag: Multiple myeloma
This quarter’s 16 approvals include a first-in-class cell therapeutic, a flurry of new options for EGFR-mutated lung cancer, and...
Researchers at the Blood Cancer Discovery Symposium presented data on multidrug resistance and clinical trial design.
As the deep reds and yellows of fall leaves give way to twinkling holiday lights, we welcome the new...
How the latest clinical therapies are helping patients and laboratory research informing future treatments.
The word myeloma stems from the Greek word “myelos,” for marrow. Indeed, this type of blood cancer begins in the plasma cells, a type...
Multiple myeloma is a cancer of antibody-producing cells—called plasma cells—that accounts for approximately 1.8 percent of new cancer cases...
By Trevan Locke, PhD Thanks to a wave of newly approved therapies in the past two decades, survival rates...
Multiple myeloma arises in immune cells called plasma cells. It is one of the most commonly diagnosed hematological malignancies...
Myeloma is the third most common blood cancer in the United States, arising in the plasma cells of the...
On Monday, the U.S. Food and Drug Administration (FDA) rounded out an exciting month for the multiple myeloma community...